Patents Examined by L. Spector
-
Patent number: 5861301Abstract: A DNA sequence encoding a novel human growth factor receptor referred to as a type III receptor tyrosine kinase is described. The amino acid sequence of the receptor is also described. The receptor has a sequence which is similar to that of the kinase domains of known type III receptor tyrosine kinases, but which is unique in its kinase insert domain sequence. The receptor binds specifically to the vascular endothelial cell growth factor.Type: GrantFiled: November 23, 1992Date of Patent: January 19, 1999Assignee: American Cayanamid CompanyInventors: Bruce Israel Terman, Miguel Eduardo Carrion
-
Screening method using a recombinant kinase insert domain containing receptor and gene encoding same
Patent number: 5766860Abstract: A DNA sequence encoding a novel human growth factor receptor referred to as a type III receptor tyrosine kinase is described. The amino acid sequence of the receptor is also described. The receptor has a sequence which is similar to that of the kinase domains of known type III receptor tyrosine kinases, but which is unique in its kinase insert domain sequence. The receptor binds specifically to the vascular endothelial cell growth factor.Type: GrantFiled: February 25, 1997Date of Patent: June 16, 1998Assignee: American Cyanamid CompanyInventors: Bruce Israel Terman, Miguel Eduardo Carrion -
Patent number: 5708141Abstract: Compositions enriched for Neutrophil Inhibitory Factor which inhibit neutrophil activity including adhesion to vascular endothelial cells are provided. Such compositions may comprise a glycoprotein isolated from nematodes, particularly of the genus Ancylostoma. These compositions are useful in the therapy of conditions which involve abnormal or undesired inflammatory responses.Type: GrantFiled: May 24, 1994Date of Patent: January 13, 1998Assignee: Corvas International, Inc.Inventors: Matthew Moyle, David L. Foster, George P. Vlasuk
-
Patent number: 5641655Abstract: DNA constructs useful in the production of thrombopoietin are disclosed. In general, the DNA constructs comprise a first DNA segment encoding a fusion of an amino-terminal secretory peptide joined to a thrombopoietin polypeptide and one or more additional DNA segments that provide for the transcription of the first segment. The secretory peptide is a native mammalian t-PA secretory peptide or may be modified to enhance proteolytic cleavage of the fusion. Also disclosed are cultured eukaryotic cells containing these DNA constructs and methods for producing thrombopoietin polypeptides through the use of the DNA constructs and cultured eukaryotic cells.Type: GrantFiled: November 30, 1994Date of Patent: June 24, 1997Assignee: ZymoGenetics, Inc.Inventors: Donald C. Foster, Mark D. Heipel, Richard D. Holly
-
Patent number: 5621090Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1A (murine flk-2), FIG. 1B (human flk-2) and FIG. 2 (murine flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1A, FIG. 1B and FIG. 2; ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation and/or differentiation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: June 26, 1992Date of Patent: April 15, 1997Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka
-
Patent number: 5573930Abstract: A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from other causes. CSF-1 is obtained in usable amounts by recombinant methods, including cloning and expression of the murine and human DNA sequences encoding this protein. Both "long" and "short" forms of this protein and muteins corresponding to the cDNA-encoded forms are disclosed.Type: GrantFiled: December 28, 1992Date of Patent: November 12, 1996Assignee: Cetus Oncology CorporationInventors: Martha B. Ladner, Janelle A. Noble, George A. Martin, Ernest S. Kawasaki, Mazie Y. Coyne, Robert F. Halenbeck, Kirston E. Koths
-
Patent number: 5559097Abstract: Methods and compositions are provided for maintaining pregnancy and preventing rejection of transplanted tissue. A polypeptide characterized as capable of isolation from conceptus tissue and capable of inhibiting mitogen induced lymphocyte blastogenesis is employed which is introduced into the uterus or systemically.Type: GrantFiled: January 12, 1990Date of Patent: September 24, 1996Assignee: Idaho Research Foundation, Inc.Inventor: R. Garth Sasser
-
Patent number: 5540926Abstract: The present invention relates to soluble ligands for the B-cell antigen, CD40, and, in particular, to human gp39 protein and soluble ligands derived therefrom which may be used in methods of promoting B-cell proliferation.Type: GrantFiled: September 4, 1992Date of Patent: July 30, 1996Assignee: Bristol-Myers Squibb CompanyInventors: Alejandro Aruffo, Diane Hollenbaugh, Jeffrey A. Ledbetter
-
Patent number: 5532347Abstract: The present invention relates to a mammalian melanocyte stimulating hormone receptor. The invention is directed toward the isolation, characterization and pharmacological use of mammalian melanocyte stimulating hormone receptor, the gene corresponding to this receptor, a recombinant eukaryotic expression construct capable of expressing a mammalian melanocyte stimulating hormone receptor in cultures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that synthesize mammalian melanocyte stimulating hormone receptor. The invention also provides methods for screening MSH.sup.R agonists and antagonists in vitro using preparations of receptor from such cultures of eukaryotic cells transformed with a recombinant eukaryotic expression construct comprising the MSH.sup.R receptor gene. The invention specifically provides human and mouse MSH.sup.R genes.Type: GrantFiled: April 10, 1992Date of Patent: July 2, 1996Assignee: State of Oregon, Acting by and Through the Oregon State Board of Higher Education on behalf of the Oregon Health Sciences University, a non-profit organizationInventors: Roger D. Cone, Kathleen G. Mountjoy
-
Patent number: 5510462Abstract: The subject invention concerns a nucleic acid comprising a nucleotide sequence encoding human interleukin-1 (IL-1), and fragments thereof, and the polypeptides and peptides obtained. Specifically, the subject invention comprises the cloning of a cDNA synthesized by reverse transcription of poly(A)RNA isolated from adherent human monocytes-stimulated with bacterial endotoxin. Human IL-1 is useful to induce the production of IL-2 by activated T-cells; it also acts on B-cells and NK-cells.Type: GrantFiled: April 25, 1988Date of Patent: April 23, 1996Assignees: New England Medical Centers Hospitals, Inc., Trustees of Tufts College, Wellesley College, Massachusetts Institute of TechnologyInventors: Philip E. Auron, Charles A. Dinarello, Andrew C. Webb, Alexander Rich, Sheldon M. Wolff
-
Patent number: 5416192Abstract: A novel family of growth regulatory proteins termed "epithelins" are described. The epithelins comprise several distinct members sharing significant structural homology. Two members of the epithelin family, epithelin 1 and epithelin 2, have been purified from natural sources. In addition, cDNA and PCR clones encoding mature and precursor epithelins from various chordate sources have been obtained and sequenced, including the complete human, mouse and rat epithelin precursors. The recombinant expression of rat epithelin precursor and mature forms is described. Purified epithelin 1 is a bifunctional growth regulator, capable of stimulating the growth of some cell types while inhibiting the growth of others. Purified epithelin 2 is functionally similar to epithelin 1 with respect to growth inhibitory bioactivity. In contrast, however, epithelin 2 is apparently not capable of eliciting the growth stimulatory activity characteristic of epithelin 1 and, in fact, antagonizes this epithelin 1 activity.Type: GrantFiled: March 13, 1991Date of Patent: May 16, 1995Assignee: Bristol-Myers Squibb CompanyInventors: Mohammed Shoyab, Gregory D. Plowman
-
Patent number: 5403586Abstract: This invention relates to the preparation of novel fusion proteins which comprise an analogue of LHRH and TraTp or an analogue of TraTp. The fusion proteins of the invention are useful as components of vaccines for the inhibition or control of reproductive functions in vertebrate hosts. The invention also relates to polynucleotide molecules encoding the fusion proteins, to transformant hosts expressing the fusion proteins and to methods of inhibiting or controlling reproductive function in vertebrate hosts using the fusion proteins or vaccines of the invention.Type: GrantFiled: June 25, 1991Date of Patent: April 4, 1995Assignee: Biotechnology Australia Ptl Ltd.Inventors: Gregory J. Russell-Jones, Andrew G. Stewart, Con G. Tsonis
-
Patent number: 5378823Abstract: Variants of type I interferons containing peptide extensions, and their production using recombinant DNA techniques, are described. Expression cassettes comprising DNA coding for the variant interferon, DNA coding for a signal peptide, and a promoter are described for use in transforming yeast and in the production of the variant interferons.Type: GrantFiled: September 11, 1992Date of Patent: January 3, 1995Assignee: Institut National de la Recherche Agronomique-I.N.R.A.Inventors: Jacques Martal, Erich DeGryse, Pierre Gaye, Madia Charlier, Gilles Charpigny, Pierrette Reinaud, Gerard Chaouat
-
Patent number: 5376639Abstract: DNAs encoding polypeptides having interleukin 1, vectors inserted with said DNAs, hosts transformed with said recombinant vectors, polypeptides having interleukin 1 activity which are produced by cultivation of the transformed hosts, derivatives of the polypeptides, pharmaceutical composition containing said polypeptides or derivatives, their use as an antitumor or antiinfectious agent, and processes for the preparation thereof.Type: GrantFiled: September 30, 1992Date of Patent: December 27, 1994Assignee: Dainippon Pharmaceutical Co., Ltd.Inventors: Masaaki Yamada, Yasuji Furutani, Michiko Yamayoshi, Mitsue Notake, Junichi Yamagishi
-
Patent number: 5328990Abstract: Macrophage Migration Inhibition Factor (MIF) can be obtained from ocular lens of various birds and mammals. The amino acid sequences of lens MIF from mice, chickens and humans has been determined and the corresponding cDNA has been cloned.Type: GrantFiled: April 26, 1991Date of Patent: July 12, 1994Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Graeme J. Wistow
-
Patent number: 5328836Abstract: Plasmids containing DNA encoding the amino acid sequence of a novel glycoprotein (TCF-II) derived from human fibroblasts, transformed cells with the plasmids and production method of rTCF-II using the transformed cells. rTCF-II can be used as a hepatocyte growth factor or a tumor cytotoxic factor.Type: GrantFiled: March 11, 1992Date of Patent: July 12, 1994Assignee: Snow Brand Milk Products Co., Ltd.Inventors: Nobuyuki Shima, Kanji Higashio, Masaya Nagao, Fumiko Oogaki, Hiroaki Takaoka, Eisuke Tsuda
-
Patent number: 5310874Abstract: Diagnostic systems, methods, polypeptides and antibodies for detecting the presence of the cytoplasmic domain of the integrin .alpha..sub.6B or .alpha..sub.Type: GrantFiled: May 3, 1991Date of Patent: May 10, 1994Assignee: The Scripps Research InstituteInventors: Richard N. Tamura, Vito Quaranta
-
Patent number: 5245010Abstract: A polypeptide which inhibits the replication of Herpes Simplex Virus and like viruses, which has the amino acid sequence of consecutive amino acids of HSV protein Vmw 65 and comprises the sequence 367 to 373: ##STR1## (identified as SEQ ID NO: 1) or a conservatively modified variant thereof, its therapeutic use and antibodies thereto.Type: GrantFiled: January 17, 1992Date of Patent: September 14, 1993Assignee: National Research Development CorporationInventors: Richard F. Greaves, Peter F. J. O'Hare
-
Patent number: 5185438Abstract: Isolated mammalian nucleic acid molecules encoding receptor protein tyrosine kinases expressed in primitive hematopoietic cells and not expressed in mature hematopoietic cells are provided. Also included are the receptors encoded by such nucleic acid molecules; the nucleic acid molecules encoding receptor protein tyrosine kinases having the sequences shown in FIG. 1 (flk-2) and FIG. 2 (flk-1); the receptor protein tyrosine kinases having the amino acid sequences shown in FIG. 1 (flk-2) and FIG. 2 (flk-1); ligands for the receptors; nucleic acid sequences that encode the ligands; and methods of stimulating the proliferation of primitive mammalian hematopoietic stem cells comprising contacting the stem cells with a ligand that binds to a receptor protein tyrosine kinase expressed in primitive mammalian hematopoietic cells and not expressed in mature hematopoietic cells.Type: GrantFiled: December 24, 1991Date of Patent: February 9, 1993Assignee: The Trustees of Princeton UniversityInventor: Ihor R. Lemischka